CEO and Professor
Nanotechnology and Regenerative Medicine Ltd & The London BioScience Innovation Centre,London
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at the cause of cardiovascular diseases and a year at Johns Hopkins Medical School looking at the treatment of liver. He published more than 647 peer-reviewed research papers and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career, Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include the development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology. He has over 15,000 media report from his achievement, include BBC, ITV, WSJ, CNN, and many more. Currently, he is working on development and commercialisation of human organs using graphene-based nanocomposite materials and stem cells technology.
His current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer. He has also developed a family of nanomaterials and nanocomposite polymers for a range of biomedical applications.